A number is circulating that is hard to ignore: an average weight loss above 28% in a phase 3 trial of retatrutide. Numbers like that get repeated far beyond the context that produced them.
So here is how to read it, including the parts a headline leaves out.
What the trial found
TRIUMPH-1 is an 80-week randomized, double-blind, placebo-controlled trial run by Eli Lilly. It enrolled 2,339 adults with obesity or overweight and at least one weight-related condition, and excluded people with diabetes. Retatrutide is an investigational once-weekly injection that activates three hormone receptors — GIP, GLP-1, and glucagon.
According to the sponsor’s announcement, average weight change at 80 weeks was:
- Placebo — 2.2%
- Retatrutide 4 mg — 19.0%
- Retatrutide 9 mg — 25.9%
- Retatrutide 12 mg — 28.3%
A prespecified extension followed 532 participants with a BMI of 35 or higher for 104 weeks; the 12 mg group’s average there was 30.3%. Participants started with an average BMI of about 40.
What the headline number is
Three things about that 28.3% are worth knowing before repeating it.
It is an average. Some participants lost more and some lost considerably less. A trial mean is a poor forecast of any one person’s result, and the same is true of every drug in this class.
It assumes people stayed on treatment. Lilly describes the headline figures as using an “efficacy estimand” — the result had every randomized participant stayed on the study drug and avoided prohibited weight-management treatments. That is a legitimate way to ask what the drug does when taken as directed. It is not the same as asking what happens to everyone who is offered it, including people who stop. Some trade coverage describes the same results as a treatment-regimen estimand, which counts everyone as randomized regardless of adherence. The two framings give different numbers, which is a good reason to wait for the full paper.
It is topline, not peer-reviewed. As of this writing, the figures come from the sponsor’s announcement and news coverage of it. A full peer-reviewed publication lets outside reviewers examine who dropped out, how missing data were handled, and what the secondary results look like. The trial was funded by the company that makes the drug, which is normal for phase 3 work and still a reason to read the detail rather than the summary.
The side effects were part of the result
The same announcement reports more gastrointestinal effects on retatrutide than on placebo. At 12 mg, nausea was reported by 42.4% of participants versus 14.8% on placebo, diarrhea by 32.0% versus 13.5%, and constipation by 26.1% versus 10.9%.
Two findings are less familiar. Dysesthesia — an abnormal skin sensation such as tingling or altered touch — was reported in 12.5% of participants at 12 mg versus 0.9% on placebo. And 11.3% of participants at 12 mg stopped treatment because of side effects, compared with 4.9% on placebo. The 4 mg group stopped at a lower rate (4.1%), which is a reminder that the top-line number and the tolerability picture move together across doses.
What the trial does not establish
- It does not tell us about people with type 2 diabetes in this trial. Separate TRIUMPH studies cover that group and report different numbers.
- It does not describe what happens after treatment ends. Eighty weeks of follow-up says little about the years that follow, and nothing about stopping.
- It does not show that more is better for everyone. Higher doses lost more weight and also produced more side effects and more discontinuations. Where that balance lands is an individual clinical judgment.
- It is not an approved treatment. Retatrutide is investigational, and its benefits and risks will be judged by regulators on the full data package.
Where this leaves compounded medications
Retatrutide is not among the medications NoBsRx provides, so this is not a product pitch. But the boundary matters for how you read everything else.
Every result above belongs to one manufacturer’s investigational product, made and studied under a formal trial protocol. Nothing in it transfers to any other preparation. The same is true of the semaglutide and tirzepatide trials people often cite: they studied the branded manufactured products. Compounded semaglutide and tirzepatide are prepared by state-licensed pharmacies for individual patients, are not FDA-approved, and have not been through those trials. If a website sells something labeled retatrutide, that product has not been through this trial either, whatever the ad implies.
The reasonable takeaway is narrow: the science of this drug class is still moving, and a large trial average is a reason to be curious, not a reason to expect a particular outcome. If you are weighing a treatment, the useful questions are the ones a licensed provider asks about your history, your other conditions, and what you are trying to improve. Our FAQ and how it works pages describe what that review looks like.
This post is general information, not medical advice. It does not describe a benefit of any NoBsRx program and is not a claim that any medication will produce a particular result. Compounded medications are not FDA-approved. Treatment is never guaranteed — eligibility and every treatment decision are made by independent licensed providers based on an individual clinical assessment, and availability varies by state. Do not start, stop, or change any medication based on an article. Talk to a licensed clinician about your own situation.